Stock Track | 3SBio Soars 5.10% Intraday on Positive Clinical Data Presentation at ASCO Annual Meeting

Stock Track05-29

3SBio's stock price soared 5.10% during intraday trading on Friday, reflecting strong investor interest in the biopharmaceutical company.

The surge follows the presentation of positive clinical data for the company's core pipeline asset, the PD-1/VEGF bispecific antibody SSGJ-707, at the ASCO Annual Meeting. According to published abstracts, a Phase II study of SSGJ-707 monotherapy in advanced non-small cell lung cancer demonstrated a confirmed objective response rate of 67.6% and a median progression-free survival of 12.4 months. Another Phase II study combining the therapy with chemotherapy as a first-line treatment for endometrial cancer showed confirmed objective response rates of 85.7% and 80.0%, respectively.

The movement occurred alongside a broader rally in the biotechnology sector, highlighting strong market sentiment for innovative drug developers. The news also comes amid a sustained boom in licensing deals within China's biotech industry, with global pharmaceutical companies actively seeking partnerships.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185948959?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 12:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185948959","market":"us","top_or_hot":-1,"title":"Stock Track | 3SBio Soars 5.10% Intraday on Positive Clinical Data Presentation at ASCO Annual Meeting","media":"Stock Track","content":"<p>3SBio's stock price soared 5.10% during intraday trading on Friday, reflecting strong investor interest in the biopharmaceutical company.</p><p>The surge follows the presentation of positive clinical data for the company's core pipeline asset, the PD-1/VEGF bispecific antibody SSGJ-707, at the ASCO Annual Meeting. According to published abstracts, a Phase II study of SSGJ-707 monotherapy in advanced non-small cell lung cancer demonstrated a confirmed objective response rate of 67.6% and a median progression-free survival of 12.4 months. Another Phase II study combining the therapy with chemotherapy as a first-line treatment for endometrial cancer showed confirmed objective response rates of 85.7% and 80.0%, respectively.</p><p>The movement occurred alongside a broader rally in the biotechnology sector, highlighting strong market sentiment for innovative drug developers. The news also comes amid a sustained boom in licensing deals within China's biotech industry, with global pharmaceutical companies actively seeking partnerships.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 3SBio Soars 5.10% Intraday on Positive Clinical Data Presentation at ASCO Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 3SBio Soars 5.10% Intraday on Positive Clinical Data Presentation at ASCO Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-29 12:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>3SBio's stock price soared 5.10% during intraday trading on Friday, reflecting strong investor interest in the biopharmaceutical company.</p><p>The surge follows the presentation of positive clinical data for the company's core pipeline asset, the PD-1/VEGF bispecific antibody SSGJ-707, at the ASCO Annual Meeting. According to published abstracts, a Phase II study of SSGJ-707 monotherapy in advanced non-small cell lung cancer demonstrated a confirmed objective response rate of 67.6% and a median progression-free survival of 12.4 months. Another Phase II study combining the therapy with chemotherapy as a first-line treatment for endometrial cancer showed confirmed objective response rates of 85.7% and 80.0%, respectively.</p><p>The movement occurred alongside a broader rally in the biotechnology sector, highlighting strong market sentiment for innovative drug developers. The news also comes amid a sustained boom in licensing deals within China's biotech industry, with global pharmaceutical companies actively seeking partnerships.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"","article_id":"1185948959","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185948959","pubTimestamp":1780027312,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"3SBio's stock price soared 5.10% during intraday trading on Friday, reflecting strong investor interest in the biopharmaceutical company.The surge follows the presentation of positive clinical data...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"个股追踪|ASCO年会公布积极临床数据三生制药盘中大涨5.10%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"3SBio's stock price soared 5.10% during intraday trading on Friday, reflecting strong investor interest in the biopharmaceutical company.The surge follows the presentation of positive clinical data for the company's core pipeline asset, the PD-1/VEGF bispecific antibody SSGJ-707, at the ASCO Annual Meeting. According to published abstracts, a Phase II study of SSGJ-707 monotherapy in advanced non-small cell lung cancer demonstrated a confirmed objective response rate of 67.6% and a median progression-free survival of 12.4 months. Another Phase II study combining the therapy with chemotherapy as a first-line treatment for endometrial cancer showed confirmed objective response rates of 85.7% and 80.0%, respectively.The movement occurred alongside a broader rally in the biotechnology sector, highlighting strong market sentiment for innovative drug developers. The news also comes amid a sustained boom in licensing deals within China's biotech industry, with global pharmaceutical companies actively seeking partnerships.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185948959","isCrawlerRequest":true}